ARCHIVES

L.I. Center At Stony Brook’s Goal Is Comprehensive Status.

This article is from The Cancer Letter archive.

Vol. 26 No. 39 | October 27, 2000

Download PDF Visit The Full Archive

Related Articles

FDA Grants Priority Review To Two Drugs in NSCLC

February 22, 2013

Phase III Trial of Imbruvica Halted, Following Increases in Progression-Free Survival

January 31, 2014

Harvard’s DePinho Becomes Finalist at MD Anderson

May 20, 2011

NCI CTEP Approved Trials For the Month of November

November 29, 2013

Broder; Cancer Act’s Special Authorities Don’t Give Director Immunity For NIH, HHS

September 27, 1991

Varmus Discusses Grant Policy, Changes in Congress and Ebola

December 12, 2014